According to The Insight Partners' research, the Europe Injectable Drug Delivery Market was valued at US$ 14,141.7 Million in 2024 and is expected to reach US$ 23,476.6 Million by 2031, registering a CAGR of 7.6% from 2025 to 2031.
Harnessing long-acting injectables and expanding role of injectable immunotherapies in cancer treatment are among the critical factors driving the growth of injectable drug delivery market.
The advent of long-acting injectable antiretrovirals represents a pivotal opportunity for HIV prevention and treatment, by offering discreet, less frequent dosing that enhances adherence and accessibility in high-burden regions. Lenacapavir, an HIV-1 capsid inhibitor administered subcutaneously twice yearly, demonstrates 96-100% efficacy in reducing HIV acquisition in clinical trials compared to background rates. Approved by the FDA in June 2025 and recommended by the WHO in July 2025, it marks a transformative step for pre-exposure prophylaxis (PrEP). It can potentially avert up to 100,000 new infections if scaled to deliver 6 million person-years of protection in the first three years. According to UNAIDS' 2025 Global AIDS Update, 1.3 million new HIV infections occurred in 2024, far exceeding the 370,000 target for 2025. 30 million people accessed antiretroviral therapy, preventing 1.8 million AIDS-related deaths. This gap underscores the need for long-acting options such as lenacapavir and cabotegravir, which reduce dosing from daily pills to bi-annual injections, improving outcomes in key populations such as adolescent girls and young women in sub-Saharan Africa, where infections remain stubbornly high. Challenges such as funding shortfalls, external health assistance projected to drop 30-40% in 2025, highlight opportunities for partnerships with organizations such as UNAIDS, and how to prioritize equitable distribution and manufacturing in low- and middle-income countries. By integrating digital tracking for adherence, these injectables could optimize supply chains, reducing stigma and logistical barriers. This opportunity addresses the persistent 1.3 million annual infections. It aligns with global goals to end AIDS by 2030, fostering innovation in sustained-release formulations and expanding to combination therapies for broader viral suppression.
On the flipside, vulnerabilities in supply chains hamper the injectable drug delivery market growth.
Europe Injectable Drug Delivery Market Segmentation Analysis:
- By Device Type, the Europe Injectable Drug Delivery Market is segmented into Conventional Drug Delivery Devices and Advanced Drug Delivery Devices. The Conventional Drug Delivery Devices segment is projected to expand at a CAGR of 6.5% during 2025 - 2031.
- By Formulation, the Europe Injectable Drug Delivery Market is segmented into Conventional Drug Delivery, Novel Drug Delivery, and Long Acting Injectable Formulations. The Conventional Drug Delivery segment is projected to expand at a CAGR of 7.1% during 2025 - 2031.
- By Formulation Packaging, the Europe Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment is projected to expand at a CAGR of 7.4% during 2025 - 2031.
- By Therapeutic Application, the Europe Injectable Drug Delivery Market is segmented into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Other Therapeutic Application. The Diabetes segment is projected to expand at a CAGR of 7.8% during 2025 - 2031.
- By Route of Administration, the Europe Injectable Drug Delivery Market is segmented into Sub-cutaneous, Intramuscular, Intravenous, and Other Route of Administration. The Sub-cutaneous segment is projected to expand at a CAGR of 7.7% during 2025 - 2031.
- By Usability, the Europe Injectable Drug Delivery Market is segmented into Disposable Injectors and Re-usable Injectors. The Disposable Injectors segment is projected to expand at a CAGR of 6.3% during 2025 - 2031.
- By End User, the Europe Injectable Drug Delivery Market is segmented into Pharmaceutical and Biopharma Companies, and CMOs and CDMOs. The Pharmaceutical and Biopharma Companies segment is projected to expand at a CAGR of 6.3% during 2025 - 2031.
By country, the Europe Injectable Drug Delivery Market is categorized into Germany, the United Kingdom, France, Spain, Italy, Rest of Europe. The Rest of Europe is projected to expand at a CAGR of 8.0% during 2025 - 2031.
Key players operating in the Injectable Drug Delivery Market are B Braun SE, Terumo Corp, Cardinal Health Inc, Phillips-Medisize, Nipro Corp, Gerresheimer AG, West Pharmaceutical Services Inc, Schott AG, Becton Dickinson and Co, Kindeva Drug Delivery LP, among others.
- Jan 2025, SCHOTT Pharma, a provider of drug containment and delivery solutions, launched the next generation of SCHOTT TOPPAC infuse polymer syringes. Developed with SCHOTT Pharma's Alliance to Zero partners, Schreiner MediPharm and Korber Pharma, the system consists of a new cap, a functional label, and carton packaging. This solution aims to address challenges hospitals face, including high levels of medication waste, inefficient manual processes, and storage constraints.
- Feb 2023, Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, expanded its product portfolio with the introduction of a disposable pen injector. Ideally suited for high-volume manufacturing, Phillips-Medisize offers pharmaceutical companies a familiar, highly competitive pen injector to facilitate faster, more efficient and cost-effective market entry.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com